New chemo combo shows promise for tough head and neck cancers

NCT ID NCT07662746

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a special form of the chemotherapy drug paclitaxel, called polymeric micelles, combined with carboplatin in 29 people with recurrent or metastatic head and neck squamous cell carcinoma. The goal is to see how well the treatment shrinks tumors and to monitor side effects. Participants receive the drugs intravenously every three weeks, continuing as long as the cancer does not worsen and side effects are manageable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
paclitaxel polymeric micelles (a form of chemotherapy) plus carboplatin
What this could lead to
If this works, it could offer a new chemotherapy option for people with head and neck cancer that has come back or spread.
What could go wrong
This is a small, early-phase trial with only 29 participants, so results may not apply to everyone. Chemotherapy side effects can be severe, and the treatment may not shrink tumors as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.